LogicBio Therapeutics (OTCMKTS:LOGC) Hits New 52-Week High – What’s Next?

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) shares hit a new 52-week high during trading on Monday. The company traded as high as $15.41 and last traded at $15.07, with a volume of 64811 shares changing hands. The stock had previously closed at $14.75.

LogicBio Therapeutics Price Performance

The firm has a market cap of $695.10 million, a P/E ratio of -20.82 and a beta of 2.11. The company has a current ratio of 1.87, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The business has a 50-day moving average of $11.93 and a two-hundred day moving average of $9.85.

LogicBio Therapeutics (OTCMKTS:LOGC) last posted its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The business had revenue of $33.60 million during the quarter, compared to analysts’ expectations of $33.60 million.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing treatments for rare and serious genetic diseases. The company’s research centered on technologies designed to modify or deliver genetic material directly inside the body.

LogicBio’s principal technology platforms included GeneRide, an in vivo gene-insertion approach intended to enable long-term expression of therapeutic genes, and GeneWare, a genome-editing platform. Its lead investigational program, LB-001, was developed as a potential treatment for methylmalonic acidemia, a rare inherited metabolic disorder.

Founded in 2014 and headquartered in Cambridge, Massachusetts, LogicBio operated primarily as a biotechnology research and development company serving the rare-disease and genetic-medicine markets.